Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanical Penetration Enhancers on Metvixia Skin Penetration
NCT02511145Phase 1Completed
- Sponsor
- Galderma
- Start
- Feb 2014
- Primary completion
- May 2014
- Modality
- Light/Condition-Responsive Prodrugs
01
Overview
Phase 1, randomised, open-label trial of methyl aminolevulinate in actinic keratosis (AK) (9 arms), sponsored by Galderma. Primary endpoint: Mean Fluorescence Levels Measured by Spectrofluorometer Probe at 3 hours. Started Feb 2014; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT02511145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02511145.